Literature DB >> 3140654

Efficacy of leuprolide therapy in children with central precocious puberty.

M S Kappy1, T Stuart, A Perelman.   

Abstract

Eight girls with central precocious puberty were treated with the long-acting gonadotropin releasing hormone analogue leuprolide acetate (Lupron) for a period of six to 18 months. Suppression of gonadotropin and estradiol secretion and regression of secondary sexual characteristics and menses were observed while patients received a subcutaneous dose of 35 to 40 micrograms/kg/d. Growth velocity was slowed in all but one patient, and the rate of skeletal maturation was slowed even more, resulting in a stabilization or improvement in predicted adult height. There were no major side effects. Although the long-term effects of leuprolide therapy cannot be determined with this study, it appears to be efficacious in the treatment of central precocious puberty.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140654     DOI: 10.1001/archpedi.1988.02150100055025

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  5 in total

1.  Recent Advances in the Treatment of Isosexual Precocious Puberty: Identifying all the problems.

Authors:  A K Leung; R G McArthur
Journal:  Can Fam Physician       Date:  1991-12       Impact factor: 3.275

2.  Precocious Puberty, GnRH Stimulation Test and Monitoring GnRH Analog Therapy.

Authors:  P S N Menon
Journal:  Indian J Pediatr       Date:  2015-09-18       Impact factor: 1.967

3.  A Gonadotropin-Releasing Hormone (GnRH) Stimulation Test Before and After GnRH Analogue Treatment for Central Precocious Puberty: Has the GnRH Test been Adequately Simplified?

Authors:  Min Sun Kim; Pyoung Han Hwang; Dae-Yeol Lee
Journal:  Indian J Pediatr       Date:  2015-05-10       Impact factor: 1.967

4.  Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

Authors:  Karen J Loechner; James T McLaughlin; Ali S Calikoglu
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-24

Review 5.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.